Related references
Note: Only part of the references are listed.Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
F. L. Locke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study
Joel Joelsson et al.
BLOOD ADVANCES (2022)
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
John H. Baird et al.
BLOOD ADVANCES (2021)
B-Cell Lymphomas, Version 5.2021 Featured Updates to the NCCN Guidelines
Andrew D. Zelenetz et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study
Simon Husby et al.
LEUKEMIA (2020)
Second Malignancies after Hematopoietic Stem Cell Transplantation
Ivetta Danylesko et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2018)
Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma
Tomas Radivoyevitch et al.
LEUKEMIA RESEARCH (2018)
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma
Christopher J. Gibson et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial
Andres J. M. Ferreri et al.
LANCET HAEMATOLOGY (2017)
Therapy-related myeloid neoplasms: when genetics and environment collide
Megan E. McNerney et al.
NATURE REVIEWS CANCER (2017)
Survival with nonmelanoma skin cancer in Germany
N. Eisemann et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma
Knut B. Smeland et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Skin Cancer Risk in Hematopoietic Stem-Cell Transplant Recipients Compared With Background Population and Renal Transplant Recipients A Population-Based Cohort Study
Silje Haukali Omland et al.
JAMA DERMATOLOGY (2016)
The Danish National Lymphoma Registry: Coverage and Data Quality
Bente Arboe et al.
PLOS ONE (2016)
The Danish National Patient Registry: a review of content, data quality, and research potential
Morten Schmidt et al.
CLINICAL EPIDEMIOLOGY (2015)
Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: a population-based cohort study
I. A. Bilmon et al.
BONE MARROW TRANSPLANTATION (2014)
The Danish Civil Registration System as a tool in epidemiology
Morten Schmidt et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2014)
Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma
Ann Y. Minn et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01
Francesco d'Amore et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls
Brian T. Hill et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With Lymphoma
Corrado Tarella et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The Danish National Prescription Registry
Helle Wallach Kildemoes et al.
SCANDINAVIAN JOURNAL OF PUBLIC HEALTH (2011)
The Danish Cancer Registry
Marianne Lundkjaer Gjerstorff
SCANDINAVIAN JOURNAL OF PUBLIC HEALTH (2011)
Danish education registers
Vibeke M. Jensen et al.
SCANDINAVIAN JOURNAL OF PUBLIC HEALTH (2011)
Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma
Tara Seshadri et al.
LEUKEMIA & LYMPHOMA (2009)
High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: A comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation
DL Forrest et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients
J Czyz et al.
ANNALS OF ONCOLOGY (2004)
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease:: a randomised trial
N Schmitz et al.
LANCET (2002)
Share Paper
